Small biotechnology companies are research intensive and develop chemical compounds that may prove to be useful drugs. A pharmaceutical company has been buying patents from two biotechnology companies. The numbers of patents that led to successful and unsuccessful drugs during the past five years for three categories of drug are in the accompanying table. Complete parts (a) through (e). Click the icon to view the numbers of patents. a) Make a contingency table for the number of successful patents with three rows for the three categories and two columns for the two companies, and give Number of Successful Patents Company A Company B Total Number of Patents Genetic Diseases Chemotherapy Company A Company B Anti-inflammatory Number of Patents Successful Unsuccessful Successful Unsuccessful Total Genetic Diseases 2 13 9 32 Chemotherapy 24 12 36 (Type whole numbers. Do not round.) Anti-inflammatory 34 49 14 12 b) Make a table similar to that in part (a), this time giving the proportion of successful patents in each cell of the table. Do not include row or column totals. Total 41 86 35 80 Proportion of Successful Patents Company A Company B Genetic Diseases Chemotherapy Print Done Anti-inflammatory (Round to three decimal places as needed.) c) Draw a graph that compares the success rate from part (b) of patents bought from Company A with those bought from Company B for each type of drug. Let "GD" represent genetic disease drugs, let "CT" represent chemotherapy drugs, and let "Al" represent anti-inflammatory drugs. Choose the correct answer below.Small biotechnology companies are research Intensive and develop chemical compounds that may prove to be useful dmgs. A pharmaceutical company has been buying patents from two biotechnology companies. The numbers of patents that led to successful and unsuccessful dmgs during the past ve years for three categories of dmg are In the accompanying table. Complete parts (a) through (e). . Click the icon to view the numbers of patents. :2) Draw a graph that compares the success rate from part (b) of patents bought from Company Awith those bought from Company B for each type of drug. Let "GD" represent genetic disease drugs, let "CT" represent chemotherapy drugs, and let "Al" represent anti-inammatory drugs. Choose the correct answer below. E Q 0.5 9,0 2 2 an a: K _ a: 3 0.4 Q 3 CA g Q B. a 0.2 I?" a IZ' 0 GD CT Al CD CT AI Drug Type Drug Type 0.3 0V 0.3 Q 2 06 06 I? . ' . ' 3 0.4 Q 3 04 Q 0 g - O D. g . a 0.2 I?" a 02 I?" o 0 GD CT Al CD CT Al Drug Type Drug Type d) Company A says that it has provided 127 patents. of which 41 were successful, giving a success rate of 32.3%. The corresponding gure for Company B is 30.4%. How would Company B respond to this claim? 0 A. Company B would respond that Company A's overall success rate is greater because Company A has submitted a higher volume of patent requests. 0 B. Company B would respond that Company As overall success rate is greater because it focuses on anti-inammatory drug patens whose overall success rate is higher than the success rate for other drug patents. O C. Company B would respond that Company A's overall success rate is greater because Company A's patent requests are subjected to a more lenient approval process. 0 D. Company B would respond that Company A's overall success rate is greater because Company B has yet to submit a new batch of patent requests for which it expects a high success rate for all drug types. urug Iype urug Iype d) CompanyAsays that it has provided 127 patents, of which 41 were successful, giving a success rate of 32.3%. The corresponding gure for Company B is 30.4%. How would Company B respond to this claim? 0 A. Company B would respond that Company A's overall success rate is greater because CompanyA has submitted a higher volume of patent requests. O B. Company B would respond that Company A's overall success rate is greater because it focuses on anti-inammatory drug patents whose overall success rate is higher than the success rate for other drug patents. O C. Company B would respond that Company A's overall success rate is greater because Company A's patent requests are subjected to a more lenient approval process. 0 D. Company B would respond that Company A's overall success rate is greater because Company B has yet to submit a new batch of patent requests for which it expects a high success rate for all drug types. e) (i) If the pharmaceutical company wants to buy a patent, which biotechnology company is better for genetic disease drugs? The pharmaceutical should buy the patent from Company V because it has a success rate with genetic disease drugs of , which is greater than the other company. (Round to three decimal places as needed.) (ii) If the pharmaceutical company wants to buy a patent, which biotechnology company is better for chemotherapy drugs? The pharmaceutical should buy the patent from Company V because it has a success rate with chemotherapy drugs of , which is greater than the other company. (Round to three decimal places as needed.) (iii) If the pharmaceutical company wants to buy a patent, which biotechnology company is better for anti-inammatory drugs? The pharmaceutical should buy the patent from Company 'V because it has a success rate with anti-inammatory drugs of . which is greater than the other company. (Round to three decimal places as needed.)